Page 3 - Ucleic Acid News Today

California Seed and Plant (CSP) Labs, a leading private plant pathology and genetics testing laboratory in California, is using VIAFLO 96 and VIAFLO 384 handheld electronic pipettes from INTEGRA Biosciences to streamline its nucleic acid extraction and sample processing workflows.

Function and form are deeply intertwined in biology. Knowing how organisms grow, adapt and reproduce requires understanding their physical structures. Hence the transformative power of the microscope across the past four centuries of science.

During the COVID-19 pandemic, pregnancy was recognized to be a high-risk condition for adverse outcomes following infection SARS-CoV-2.

Researchers developed a novel algorithm to analyze large genomic datasets of RNA viruses, applying it to SARS-CoV-2 and SARS-CoV.

For many people with fragile X, the mutated gene that causes symptoms is active rather than silenced. Thom Leach/Science Photo LibraryFragile X syndrome is a genetic disorder caused by a mutation in a gene that lies at the tip of the X chromosome. It is linked to autism spectrum disorders. People with fragile X experience a range of symptoms that include cognitive impairment, developmental and speech delays and hyperactivity. They may also have some physical features such as large ears and foreh

Researchers discussed the role of artificial intelligence (AI) in preventing outbreaks of infectious diseases and future pandemics.

Global Nucleic Acid Therapeutics CDMO Market to Reach $14.19 Billion by 2033 – BIS Research Market Intelligence Report

New research has identified a potential method for treating fragile X syndrome, a leading cause of autism spectrum disorders that is characterized by an inherited repeat of certain nucleotides within the DNA sequence of the FMR1 gene.

Researchers characterized the children with severe acute respiratory syndrome coronavirus 2 reinfection.

Exothera has partnered with Quantoom Biosciences to gain access to Quantoom’s Nfinity technology, a continuous production platform for RNA. The partnership will enable Exothera to be the first CDMO in the world to offer this off-the-shelf process for the continuous production of RNA as a service. Continuous manufacturing of RNA can provide significant advantages in terms of efficiency, productivity, quality control, cost-effectiveness, and scalability.